Innocan Pharma Meets Pre-Clinical End-Point in Pilot Pain Study on Dogs Using LPT Liposome Technology

MarketWatch’s news department was not involved in the creation of this content.

6 dogs suffering from osteoarthritis and lameness demonstrated CBD concentrations 6 weeks after a single injection

Pain and well-being scores improved after treatment

Herzliya, Israel and Calgary, Alberta, August 17, 2022 (Newsfile Corp via COMTEX) — Herzliya, Israel and Calgary, Alberta — (Newsfile Corp. – August 17, 2022) – Innocan Pharma Corporation (CSE: INNO) (FSE) : IP4) (OTCQB: INNPF) (the “Company” or “Innocan”) is pleased to announce positive partial results in a pain pilot study in dogs using the LPT CBD liposomal delivery platform.

Six dogs suffering from osteoarthritis and lameness that were treated with oral pain relievers but still in pain were given a single subcutaneous injection of liposomal CBD in addition to their usual pain relievers. CBD concentrations were observed for 6 weeks after injection of liposomal CBD in the plasma of dogs. Owners reported that the dogs’ pain and well-being scores improved for several weeks after the injection. The results show that LPT technology has the potential to provide additional analgesia in dogs in pain.

On August 11, 2022, Innocan reported the first results of a study in dogs showing near 100% bioavailability of CBD using Innocan’s LPT technology, compared to a bioavailability of 6.5-20 % in humans when administered orally.

Professor Chezy Barenholz of the Hebrew University said: “The challenge of demonstrating significant efficacy is the core hurdle of CBD. We are proud to report that we are up to this challenge. Our team at R&D is working tirelessly and we look forward to more information and results soon.”

“Innocan is pleased to report today another important milestone we have reached on the road to market. We will learn the results as much as possible and provide updates and reports to the public when it is complete. These are exciting times for me and at Innocan, as we can see our vision manifest in clinical reality,” said Innocan CEO Iris Bincovich.

Innocan’s unique LPT solution

By administering injectable CBD encapsulated in liposomes (the LPT platform), Innocan seeks to achieve long-lasting, therapeutic levels of CBD in the body. Innocan believes this will create a much more effective and prolonged therapeutic effect. Innocan conducted a series of experiments of its LPT platform in animals. These experiments have shown initial positive results, supporting the feasibility of Innocan’s intention to make CBD available to humans and animals for extended periods with a single injection. Innocan’s unique delivery method allows for sustained release of CBD into the bloodstream with improved pharmacokinetic (PK) performance. The research is conducted in collaboration with the Hebrew University of Jerusalem and indicates the potential of the company’s technology to deliver cannabinoids into the bloodstream more effectively.

About Innocan

Innocan is a pharmaceutical technology company that operates under two main segments: Pharmacy and Consumer Welfare. In the pharmaceuticals segment, Innocan focuses on the development of innovative drug delivery platform technologies incorporating cannabinoid science, to treat various conditions to improve patients’ quality of life. This segment includes two drug delivery technologies: (i) LPT CBD-loaded liposome platform that facilitates precise dosing and prolonged, controlled release of CBD into the bloodstream. Research into the LPT delivery platform is in preclinical testing for two indications: epilepsy and pain management. (ii) 160 CBD-loaded exosomes platform that may have the potential to provide a highly synergistic effect of regenerative and anti-inflammatory properties targeting the Central Nervous System (CNS). In the Consumer Wellness segment, Innocan develops and markets a broad portfolio of innovative, high-performance self-care products to promote a healthier lifestyle. In this segment, Innocan has established a joint venture named BI Sky Global LTD that focuses on developing targeted advanced online sales.

For more information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+972-54-3012842
info@innocanpharma.com

NEITHER THE CANADIAN STOCK EXCHANGE NOR ITS REGULATORY SERVICE PROVIDER HAS REVIEWED NOR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS PUBLICATION.

Caution regarding forward-looking information

Certain information set forth in this press release, including, without limitation, information about research and development, collaborations, potential filings with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects derived from the company’s research activities and/or products, the necessary regulatory approvals and the time of market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this press release is based on certain expectations and key assumptions made by Innocan, including expectations and assumptions regarding the anticipated benefits of products, the satisfaction of regulatory requirements in various jurisdictions and the successful completion of production agreements and necessary distribution. .

Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this press release. Key risks and uncertainties include, but are not limited to: general global and local (domestic) economic, market and business conditions; governmental and regulatory requirements and actions of governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks inherent in the nature of product distribution, including import/export issues and the failure to obtain (or to do so in a timely manner) required regulatory and other approvals and availability in each market for inputs and finished products. products The expected timing of market entry may change for various reasons, including the inability to secure necessary regulatory requirements or the need for additional time to conclude and/or satisfy manufacturing and distribution agreements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this press release regarding the timing of product distribution. A comprehensive discussion of other risks affecting Innocan can also be found in Innocan’s public reports and documents which are available on Innocan’s profile at www.sedar.com.

Readers are cautioned not to place undue reliance on forward-looking information, as actual results may differ materially from the forward-looking information. Innocan undertakes no obligation to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as required by applicable law.

To view the source version of this press release, visit

COMTEX_412442199/2523/2022-08-17T03:01:49

Is there a problem with this press release? Please contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch customer service through our Customer Center.

copyright (c) newsfile corp. 2022. all rights reserved

MarketWatch’s news department was not involved in the creation of this content.

Source link

You May Also Like

About the Author: SteveSossin

Welcome! I keep up on all the latest cbd and thc news!